Giulia Cattaneo
@GCattaneoPhDProject Scientist @CedarsSinai @DeptSurgeryCS Cancer immunology & Immunotherapy
Similar User
@luisjohnson1570
@Luca1393
@drsurg_ankur
@MsAigbokhae
@nappiclementejr
@kapilsiddiraj
@docparthanayak
@rbhavanirao
Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. @bqrn1 @iisifrigerio @CFerroneMD @GayaSpolverato sciencedirect.com/science/articl…
Our Editorial on the new REDISCOVER guidelines addressing BR/LA PDAC is now available online @UpdatesSurgery @CFerroneMD @DeptSurgeryCS link.springer.com/article/10.100…
Study Reveals Potential Immunotherapy Advance for Pancreatic Cancer @DeptSurgeryCS cedars-sinai.org/newsroom/study…
I am really grateful for this amazing opportunity to continue my research on Spinocerebellar ataxias in the Kuo lab @KuoMDCerebellum at @Columbia! Thanks @NAF_Ataxia! #spinocerebellarataxia #cerebellum ataxia.org/2024-naf-resea…
#FerroneLab is hiring a highly motivated postdoc with interest in HPB surgical oncology and translational cancer immunology/immuno-oncology nature.com/naturecareers/… @DeptSurgeryCS
Check this out! Our last paper showing high B7–H3 expression suppresses the positive impact of HLA class I expression on survival in PDAC. @MGHCancerCenter @MGH_RI @MVentinMD @ShahrzadAryaMD @CFerroneMD @JenWargoMD sciencedirect.com/science/articl…
We provide an updated analysis showing no difference in actual 5y survival in node-positive PDAC patients regardless of the common hepatic artery lymph node involvement. @MGHSurgery @JournalofGISurg @SSATNews @DDWMeeting sciencedirect.com/science/articl…
Now online!🍾 CSPG4 CAR-redirected #CytokineInducedKiller lymphocytes (CIK) as effective cellular #immunotherapy for HLA class I defective #melanoma open access🔓 jeccr.biomedcentral.com/articles/10.11… #ChimericAntigenReceptor @IREISGufficiale
Check this out! Now on @JournalofExper1 our latest work showing the therapeutic potential of CSPG4-redirected CIK cells in the challenging setting of HLA defective melanoma. jeccr.biomedcentral.com/articles/10.11…
The following review led by Dr. Marco Ventin (@MVentinMD) focuses on linking the efficacy and safety of CAR T-cell therapy with tumor burden. @harvardmed Learn more at @JAMAOnc: 📑 bit.ly/3udhn8d
Thanks @JAMAOnc for giving space to our work which highlights the implications of high tumor burden and immune system dysfunction on CAR T cell therapy efficacy. @CAR_TCell @MGHCancerCenter @DeptSurgeryCS
This review provides a comprehensive view on how high tumor burden and tumor-burdened immune system dysfunction play central roles in CAR T cell therapy efficacy and safety. ja.ma/49rKWmJ @MVentinMD @GCattaneoPhD @CFerroneMD
Effective CAR T cell therapy is highly dependant on patients’ systemic and local tumor immune contexture. Thanks @JAMAOnc for giving space to our work on the Implications of High Tumor Burden on CAR T Cell Immunotherapy @MGHCancerCenter @DeptSurgeryCS @CAR_TCell
This review provides a comprehensive view on how high tumor burden and tumor-burdened immune system dysfunction play central roles in CAR T cell therapy efficacy and safety. ja.ma/49rKWmJ @MVentinMD @GCattaneoPhD @CFerroneMD
Out today @NatureComms! We show solid tumor cancer cell stress drives non-genetic reprogramming of the TME and CAR T cell phenotypic switch. @MGHSurgery @MGHCancerCenter @harvardmed nature.com/articles/s4146…
Our latest manuscript @NatureComms unveils a groundbreaking approach to enhance CAR T-cell therapy for solid tumors. By reprogramming CAR T cells through tumor cell stress exposure, we're addressing multiple challenges. nature.com/articles/s4146… @MGHSurgery @MGHCancerCenter
Check this out! A novel non genetic strategy to drive functional and phenotypical reprogramming of CAR T cells. doi.org/10.1038/s41467… @NatureComms @MGHCancerCenter @ShahrzadAryaMD @MVentinMD @CFerroneMD @Oncoinfo_it @CAR_TCell
Surgically treated TSC-PNETs showed promising results with 0% recurrence & no PNET-related deaths. Could conservative strategies be an alternative? More insights in our study link.springer.com/article/10.124… @CFerroneMD @MVentinMD @AnnSurgOncol @MGHCancerCenter @MGHSurgery @CedarsSinaiMed
Our team led by @CFerroneMD & co-author @ShahrzadAryaMD at @AnnSurgOncol compared long-term outcomes of surgically resected TSC-PNETs & sporadic PNETs. #PancreaticTumors #TSC link.springer.com/article/10.124…
Our team led by @CFerroneMD & co-author @ShahrzadAryaMD at @AnnSurgOncol compared long-term outcomes of surgically resected TSC-PNETs & sporadic PNETs. #PancreaticTumors #TSC link.springer.com/article/10.124…
Check out our last paper published in @FrontOncology #FerroneLab
Happy to see out @FrontOncology our contribution on the role of non-conventional low-dose radiation to enhance CAR T cell therapy in solid tumors. @MGHSurgery #FerroneLab frontiersin.org/journals/oncol…
United States Trends
- 1. #WWERaw 27,9 B posts
- 2. Seth 26,5 B posts
- 3. Seth 26,5 B posts
- 4. Delaware 32,4 B posts
- 5. Broncos 25 B posts
- 6. Dustin Hopkins N/A
- 7. #DawgPound 2.271 posts
- 8. Lyra 3.529 posts
- 9. #SupermanAndLois 7.014 posts
- 10. #CLEvsDEN 3.449 posts
- 11. #ChristmasCrunchSweepstakes N/A
- 12. Jerry Jeudy 1.507 posts
- 13. Sutton 4.681 posts
- 14. Madrimov 2.714 posts
- 15. Jack Hughes N/A
- 16. Monday Night Football 4.564 posts
- 17. Circus 29,5 B posts
- 18. Taylor Lorenz 1.711 posts
- 19. Tacky 3.586 posts
- 20. Jameis Winston 3.516 posts
Something went wrong.
Something went wrong.